Xtandi demonstrates significant improvement in OS in nmCRPC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The phase III PROSPER trial, which evaluated Xtandi (enzalutamide) plus androgen deprivation therapy versus placebo plus ADT in men with non-metastatic castration-resistant prostate cancer, demonstrated a statistically significant improvement in overall survival in patients with nmCRPC who were treated with Xtandi plus ADT.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

As Ben Ho Park sees it, the mission of a cancer researcher doesn’t stop at the water’s edge. It follows that Park’s new role as director of Vanderbilt-Ingram Cancer Center is inseparable from his role as an executive of the Global Cancer Institute, a nonprofit that works with healthcare providers in low- and middle-income countries to improve survival rates for underserved cancer patients.

Login